Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adocia Signs an Exclusive License on a Nanotechnology

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Preclinical results have already demonstrated its remarkable action on solid tumors.

Adocia has announced the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert (SATT Aquitaine).

This agreement grants Adocia the development and commercialization rights over an international patent application protecting a nanotechnology for drug delivery in the field of healthcare. The cash position of the company is not significantly impacted by this acquisition, for which financial terms remain confidential.

Adocia has taken this opportunity to develop a new technology for oncology whilst pursuing as scheduled the clinical studies plan on its three insulin products and on its product for chronic wound healing. Its scientific expertise in drug delivery will be crucial for rapid industrial development.

The new technology, called DriveIn® was developed by Professor Sebastien Lecommandoux and his team at the Laboratoire de Chimie des Polymeres Organiques (LCPO, UMR5629 CNRS - Universite de Bordeaux I - Institut polytechnique de Bordeaux). It is remarkably efficient in carrying active molecules and delivering them within solid tumors. This work has been published in multiple peer-reviewed journals.

Adocia will adopt a dual strategy for the development of this technology. It intends to develop proprietary products based on doxorubicin and docetaxel, two of the most used anti-tumoral treatments, which could greatly benefit from an enhanced intra-cellular delivery. Adocia will also propose the DriveIn technology to pharmaceutical companies to optimize the efficacy of their own proprietary molecules.

Research is ongoing to develop new treatments in oncology, but also to improve the performance of commercial products while limiting their side effects. Today, one of the main challenges is to more efficiently target the molecules towards solid tumors, so as to concentrate them on cancer cells and limit the damage to healthy tissues.

The innovation in DriveIn consists in its using nanoparticles that have a surface completely made of hyaluronan, a biopolymer naturally present in the human body, known to interact with the CD44 cell receptor. This receptor is overexpressed in a large number of solid tumors, thus allowing DriveIn nanoparticles to efficiently reach and penetrate cancer cells. This is known to be a limitation of current therapies.

“The remarkable ability of DriveIn nanoparticles to diffuse throughout the tumor and get actively internalized by cancer cells has convinced us of the uniqueness of this technology,” said Olivier Soula, director of research and development at Adocia. “Our primary objective is to develop a proprietary formulation for treating ovarian cancer and to launch the first clinical trial in Q4 2014.”

“We are very happy with this acquisition now that the products based on the BioChaperone technology are in clinical development,” said Gerard Soula, Adocia’s CEO. “Considering our team’s expertise, this new platform in nanotechnology is an exceptional opportunity to fight cancer by improving the efficacy of already approved treatments.”
 
Next scheduled events
Adocia will attend ODDO Midcap Forum, Lyon, France – January 9th and 10th, 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adocia Reports Positive Results from Phase IIa Clinical Study of BioChaperone® Lispro
The ultra-fast action of BioChaperone Lispro should make a positive impact on short and long-term glycemic control, improving the medical benefit for patients.
Friday, April 11, 2014
Adocia Confirms Positive Clinical Results for its BioChaperone® Combo
BioChaperone Combo is the first combination based on insulin glargine to show a fast and long action in type I diabetic patients.
Friday, March 21, 2014
Adocia Strengthens its Diabetic Foot Ulcer Patent Portfolio
The patent on the BioChaperone® polymer used in the PDGF composition recently granted in the United States.
Thursday, January 16, 2014
Adocia Launches Phase IIa Clinical Trial for its Ultra-fast Acting Formulation of Analog Insulin
The aim is to confirm on type I diabetic patients the positive results obtained during phase I.
Tuesday, January 07, 2014
Adocia Announces Initiation of a Clinical Trial on its Combination of Glargine and Lispro
This phase I/II clinical trial on Type I diabetics seeks to compare the performance of this Combo based on insulin Glargine with HumalogMix®.
Monday, November 18, 2013
Adocia Announces Revenues of EUR 4.7 M for the Third Quarter of 2013
The company maintained available cash at EUR 22.7 M.
Thursday, October 24, 2013
Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog
Adocia and Lilly terminate collaboration.
Tuesday, July 30, 2013
Adocia Announces its Phase III Development Program for the Treatment of DFU
This program has been validated by scientific advice from the European Medicines Agency.
Wednesday, March 20, 2013
Adocia Announces a Strengthened Intellectual Property on its Lead Project for its Chronic Wounds Treatment
USPTO and EPO have issued a patent to Adocia covering BioChaperone PDGF formulations for chronic wound treatment.
Thursday, June 14, 2012
Adocia Reports Positive Phase II Clinical Results for the Treatment of Diabetic Foot Ulcer
Adocia’s spray formulation of PDGF-BB, combined with BioChaperone®, has been evaluated versus Regranex®, gel of PDGF-BB.
Tuesday, April 24, 2012
Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
Study on healthy volunteers of a formulation using Adocia’s BioChaperone® platform showed fast onset of action, excellent local tolerance, absence of pain and low inter-patient variability.
Wednesday, March 16, 2011
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!